Iga Swiatek Accepts One-Month Doping Ban Following Positive Test

World number two and five-time Grand Slam champion Iga Swiatek, who has secured the French Open title in four of the last five seasons, has agreed to a one-month suspension following a positive test for a prohibited substance. The 23-year-old, currently the reigning French Open champion, tested positive for trimetazidine (TMZ), a heart medication, from an out-of-competition sample collected in August 2024, at which time she held the world number one ranking. The International Tennis Integrity Agency (ITIA) acknowledged that the positive result stemmed from contamination of melatonin, a regulated non-prescription medication produced and sold in Poland, which Swiatek used to address jet lag and sleep problems. Consequently, Swiatek’s degree of culpability was assessed as being at the lowest possible point within the ‘No Significant Fault or Negligence’ category. On Instagram, she stated: “In the last two-and-a-half months I was subject to strict ITIA proceedings, which confirmed my innocence.” She further commented: “The only positive doping test in my career, showing unbelievably low level of a banned substance I’ve never heard about before, put everything I’ve worked so hard for my entire life into question.” “Both me and my team had to deal with tremendous stress and anxiety. Now everything has been carefully explained, and with a clean slate I can go back to what I love most,” she added. Swiatek faced a provisional suspension starting September 12, but successfully appealed it, leading her to miss three tournaments. The Polish athlete lodged an appeal against the provisional suspension on September 22, informing an independent tribunal that the origin of the positive test had been determined to be a contaminated medication produced in Poland. Following tests that corroborated Swiatek’s explanation, the ITIA proposed a one-month suspension, which she accepted on Wednesday. Given that her provisional suspension was lifted on October 4, Swiatek’s period of ineligibility is set to conclude on December 4, 2024. The Polish tennis player was also required to relinquish the prize money earned from reaching the semi-finals of the Cincinnati Open, the tournament immediately succeeding the test. Swiatek further stated: “I admit this situation hit me hard because all my life I strived to have a career that could be an example for generations to come.” She continued: “I have a sense this situation could undermine the image I’ve been building for years, which is why I hope you will understand I had no control over it and could do nothing to prevent this unfortunate turn of events.” “Without my supporters I am not sure I would have been able to find the strength to carry on and keep fighting. Now I have fought the toughest battle in my life, and I hope you will stay with me and keep supporting me,” she concluded. Beyond her fourth French Open victory, Swiatek secured titles in Doha, Indian Wells, Madrid, and Rome during 2024. She was unable to compete in the Korea Open (September 16-22), China Open (September 25 – October 6), and Wuhan Open (October 7-13, as she was suspended during the entry deadline). The ITIA opted not to publicize her provisional suspension since the player successfully appealed the notice within 10 days. Karen Moorhouse, ITIA chief executive, commented: “Once the source of the TMZ had been established, it became clear that this was a highly unusual instance of a contaminated product, which in Poland is a regulated medicine.” She added: “However, the product does not have the same designation globally, and the fact that a product is a regulated medication in one country cannot of itself be sufficient to avoid any level of fault. Taking into account the nature of the medication, and all the circumstances, it does place that fault at the lowest end of the scale.” Swiatek’s suspension follows a similar incident in March, when men’s world number one Jannik Sinner tested positive for clostebol. While the ITIA determined that there was “no fault or negligence” on the part of the 23-year-old Italian, the World Anti-Doping Agency (Wada) has initiated an appeal to the Court of Arbitration for Sport (Cas). The Women’s Tennis Association (WTA) recognized the ITIA’s decision in a statement, extending its “full support” to Swiatek during what it described as a “difficult time.” The WTA added: “Iga has consistently demonstrated a strong commitment to fair play and upholding the principles of clean sport, and this unfortunate incident highlights the challenges athletes face in navigating the use of medications and supplements.” “The WTA remains steadfast in our support for a clean sport and the rigorous processes that protect the integrity of competition. We also emphasise that athletes must take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to prohibited substances can have significant consequences,” the statement concluded. Analysis by BBC Sport tennis correspondent Russell Fuller: Similar to Sinner, Swiatek encountered issues with a medication available for purchase over the counter in her native country. The parallels extend further, as both athletes successfully contested the mandatory provisional suspension typically associated with this category of violation. A significant factor in their success was the ability of both to promptly identify the source of the positive test, which for Swiatek was verified by a Wada-accredited laboratory located in Utah. In her social media communication, she expressed her anticipation of returning to her passion with a “clean slate.” However, Swiatek also acknowledged a concern that this situation might damage the public image she has cultivated over many years – a sentiment previously voiced by Sinner earlier this year.